Sun Pharma Secures Investment Grade Ratings for Organon Acquisition

Moody's Baa1 and S&P Global BBB+ Ratings assigned with Stable outlook.

Reader Takeaway: Strong cash flows support acquisition leverage, but integration of a large, complex portfolio carries execution risks.

What just happened

Sun Pharmaceutical Industries Limited has received international issuer credit ratings from Moody's (Baa1) and S&P Global (BBB+). Both agencies have assigned a 'Stable' outlook, factoring in the company’s planned $11.75 billion acquisition of Organon & Co. The transaction is currently expected to close in the first quarter of 2027, pending necessary regulatory clearances.

Why this matters

The ratings provide institutional validation of Sun Pharma’s financial health as it prepares to undertake its largest acquisition to date. While the acquisition involves significant capital, the agencies have expressed confidence in the company’s ability to manage its balance sheet and deleverage over the 18 months following the deal’s completion.

Financial and Leverage Outlook

Moody’s projects that the company's adjusted gross debt/EBITDA will climb to approximately 3.0x by March 2027—a shift from its historical sub-1.0x levels. Sun Pharma has secured a $12 billion committed bridge loan facility to fund the transaction. The company intends to reduce this leverage to 2.0x within 18 months post-closing, driven by roughly $350 million in projected cost synergies and sustained cash flow generation.

Strategic Rationale

The acquisition is designed to scale Sun Pharma’s presence in women’s health, biosimilars, and branded medicines. By absorbing Organon’s commercial infrastructure, the company plans to penetrate new growth markets like China and Korea, significantly enhancing its global product and geographic diversification.

Risks to watch

Integration complexity is a primary concern, as Organon is larger than previous acquisitions like Taro. Additionally, investors should track FDA compliance at Sun Pharma’s Indian manufacturing sites, specifically the Halol plant, where prior observations remain a factor. Finally, the long-term performance and potential patent expiry of Organon’s key product, Nexplanon, will be vital for the deal’s return on investment.

What to track next

Watch for updates on regulatory approvals for the transaction and any further announcements regarding the financing structure of the $12 billion bridge facility.